This work identifies CD8−NOS2+COX2+ and CD8−NOS2−COX2+ unique cellular neighborhoods that drive the tumor immune spatial architecture of CD8+ T cells predictive of clinical outcome and can be targeted with clinically available NOS inhibitors and NSAIDs. This evidence concerns the gene CD8A and neoplasm.